SCHEMBL3244492

SCHEMBL3244492

O=S(=O)(c1ccccc1Cl)N1CCCNCC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.74
MAPK1 P28482 3/20 0.74
CYP2D6 P10635 3/20 0.74
MYLK Q15746 3/20 0.74
TP53 P04637 2/20 0.74
CYP1A2 P05177 2/20 0.74
NFKB1 P19838 2/20 0.74
MEN1 O00255 2/20 0.74
KMT2A Q03164 2/20 0.74
CYP2C9 P11712 2/20 0.74
MAPT P10636 3/20 0.72
GMNN O75496 2/20 0.72
LMNA P02545 2/20 0.72
PMP22 Q01453 1/20 0.72
ROCK1 Q13464 5/20 0.60
TSHR P16473 3/20 0.60
CYP2C19 P33261 2/20 0.60
MTOR P42345 1/20 0.60
RAB9A P51151 1/20 0.60
NPSR1 Q6W5P4 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30610303 0.94 USP2 (0.66) CYP3A4MAPK1CYP2D6MYLKTP53
SCHEMBL654111 0.94 USP2 (0.66) CYP3A4MAPK1CYP2D6MYLKTP53
SCHEMBL2869228 0.85 CYP3A4 (1.00) CYP3A4MAPK1CYP2D6MYLKTP53
SCHEMBL2959421 0.85 POLB (0.57) CYP3A4MAPK1CYP2D6MYLKTP53
Hydrochloric Acid SCHEMBL29370764 0.84 MAPK1 (1.00) CYP3A4MAPK1CYP2D6MYLKTP53
Hydrochloric Acid SCHEMBL1848494 0.84 MAPK1 (1.00) CYP3A4MAPK1CYP2D6MYLKTP53
SCHEMBL4555453 0.83 TSHR (0.78) CYP3A4MAPK1MEN1KMT2ACYP2C9
SCHEMBL31684034 0.83 TSHR (0.78) CYP3A4MAPK1MEN1KMT2ACYP2C9
Hydrochloric Acid SCHEMBL1986979 0.83 CYP3A4 (0.95) CYP3A4MAPK1CYP2D6MYLKTP53
SCHEMBL3245089 0.83 CYP3A4 (0.60) CYP3A4MAPK1CYP2D6MYLKTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586577-B2 Diazepane acetamide derivatives as selective 11B-HSD1 inhibitors MERCK PATENT GMBH (DE) 2013-11-19 US disclosed
US-20120283247-A1 DIAZEPANE ACETAMIDE DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS MERCK PATENT GMBH (DE) 2012-11-08 US disclosed
US-8242107-B2 Diazepane-acetamide derivatives as selective 11β-HSD1 inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-08-14 US disclosed
EP-2078001-B8 DIAZEPANE-ACETAMIDE DERIVATIVES AS SELECTIVE 11 -HSD1 INHIBITORS MERCK PATENT GMBH (DE) 2010-12-15 EP disclosed
EP-2078001-B1 DIAZEPANE-ACETAMIDE DERIVATIVES AS SELECTIVE 11 -HSD1 INHIBITORS MERCK PATENT GMBH (DE) 2010-05-12 EP disclosed
US-20100069365-A1 Diazepane-acetamide derivatives as selective 11B-HSD1 inhibitors MERCK PATENT GMBH (DE) 2010-03-18 US disclosed
EP-2078001-A1 DIAZEPANE-ACETAMIDE DERIVATIVES AS SELECTIVE 11 -HSD1 INHIBITORS Merk Patent Gmbh (DE) 2009-07-15 EP disclosed
WO-2008052638-A1 DIAZEPANE-ACETAMIDE DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS MERK PATENT GMBH (DE) 2008-05-08 WO disclosed
EP-1918285-A1 Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors Merck Sante (FR) 2008-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069365-A1 Diazepane-acetamide derivatives as selective 11B-HSD1 inhibitors HSD11B1, HSD11B2, HSD17B1 CYP3A4 285/4885MAPK1 519/4885CYP2D6 357/4885
US-20120283247-A1 DIAZEPANE ACETAMIDE DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS HSD11B1, HSD11B2, HSD17B1 CYP3A4 336/4885MAPK1 476/4885CYP2D6 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.